SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Longeveron Inc. (LGVN) News

Track canonical SquawkNews coverage tagged to LGVN, Longeveron Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 10 indexed stories across 8 publication days and is ordered by the same first-publication timeline used by LiveCast.

Symbol LGVN Asset equity Sector Markets 90 days 9 Last 2.66 Updated Sep 23, 2026, 08:04 PM UTC Open live news feed
L Longeveron reports ELPIS II misses primary endpoint; to analyze data, explore strategic options Longeveron announced ELPIS II topline results showing the Phase 2b trial of laromestrocel in HLHS did not meet its primary endpoint of RVEF improvement at 12 months.Key Highlights:Original SEC Filing: Longeveron Inc. [ L REGULATION | Sep 23, 2026, 08:04 PM UTC H Why Generac Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket Shares of Generac Holdings Inc (NYSE: GNRC ) rose sharply in pre-market trading after the company announced a supply agreement with Amazon.com Inc. (NASDAQ: AMZN ) for data center backup generators. Generac and Amazon en LIVE | Sep 17, 2026, 09:19 AM UTC H Longeveron shares plunge after Phase 2b stem-cell trial misses endpoint Longeveron said its Phase 2b trial of a stem-cell therapy for a pediatric heart condition failed to meet its primary endpoint, sending shares down about 60% to $2.65 in after-hours trading. EARNINGS | Sep 16, 2026, 10:27 PM UTC M Longeveron explores options after laromestrocel misses Phase 2b endpoint Longeveron said it has begun exploring options to maximize shareholder value after its stem cell therapy laromestrocel failed to meet the primary endpoint in a Phase 2b trial for a heart condition in children. EARNINGS | Sep 16, 2026, 09:55 PM UTC M Longeveron ELPIS II misses HLHS primary endpoint; strategic review starts Longeveron said its ELPIS II trial in HLHS did not meet the primary RVEF endpoint (LS mean diff โˆ’0.7 pts; p=0.8336) and has begun a review of options to maximize shareholder value, including cash conservation. Safety was EARNINGS | Sep 16, 2026, 09:31 PM UTC L Longeveron regains Nasdaq $1.00 minimum bid compliance after 10-day close streak Longeveron regained compliance with Nasdaq's $1.00 minimum bid requirement following a 10-business-day closing price streak at or above $1.00.Key Highlights:Original SEC Filing: Longeveron Inc. [ LGVN ] - 8-K - Sep. 14, REGULATION | Sep 14, 2026, 08:26 PM UTC L Longeveron to present at H.C. Wainwright 28th Global Investment Conference Longeveron Inc. said it will participate in the H.C. Wainwright 28th Annual Global Investment Conference. EQUITY | Sep 03, 2026, 01:17 PM UTC H U.S. stock futures rise as sanctions and yields weigh U.S. stock futures advance, with Dow Jones, S&P 500 and Nasdaq 100 futures higher, as Scott Bessent expands sanctions on Iran and 10-year Treasury yields stand at 4.71%. EARNINGS | Aug 25, 2026, 09:38 AM UTC M Longeveron appoints Nirav Jhaveri as chief financial officer Longeveron appoints Nirav Jhaveri as chief financial officer, while Marie Washburn steps down as CFO and returns to corporate controller. MNA | Aug 19, 2026, 08:06 PM UTC L 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Can Fite Biopharma (AMEX: CANF ) stock moved upwards by 52.0% to $4.52 during Wednesday's pre-market session. The company's market cap stands at $6.3 million. Atlantic International (NASDAQ: ATLN ) shares rose 17 EQUITY | Jul 01, 2026, 12:05 PM UTC